Drug elimination from the body primarily occurs through metabolic and excretion pathways. Hepatic metabolism transforms lipophilic drugs into hydrophilic forms for excretion, typically via enzymatic processes classified as phase I (modification) and phase II (conjugation). Renal excretion eliminates drugs and metabolites through filtration and secretion in the kidneys. Impairment in liver or kidney function can hinder these processes, delaying drug clearance and extending the drug’s half-life. This prolongs the drug’s presence in the body, increasing its therapeutic duration and elevating the risk of toxicity.
An extended half-life (t₁/₂) directly increases a drug's effective duration (teff) without altering the dose. Increasing the dosage alone may not maintain adequate plasma concentrations in patients with high metabolic or clearance rates. In such cases, strategies that prolong the drug’s half-life can help sustain therapeutic levels. This can involve structural modifications to the drug or co-administration with agents that inhibit its elimination.
For instance, rapidly excreted antibiotics, such as penicillin and cephalosporin, are often co-administered with probenecid, which competitively inhibits renal tubular secretion. This slows their elimination, thereby enhancing efficacy and duration. Similarly, the combination drug Augmentin includes amoxicillin and clavulanic acid. Clavulanic acid acts as a suicide inhibitor of bacterial β-lactamase, an enzyme that degrades β-lactam antibiotics. By inhibiting this bacterial enzyme, clavulanic acid prevents amoxicillin breakdown by the bacteria and thereby expands its antimicrobial spectrum against β-lactamase-producing bacteria.
These pharmacological strategies optimize drug action, especially in conditions where rapid elimination limits efficacy. Understanding and manipulating metabolism and excretion pathways allow for more effective and safer therapeutic interventions.
Metabolic and excretion pathways eliminate drugs from the body.
Hepatic or renal disorders can impair these pathways, slowing elimination and extending the drug’s half-life.
This prolongs the drug’s duration in the body, increasing the risk of toxicity.
An extended half-life, t1/2, directly prolongs its therapeutic duration, teff, even at the same dose.
In patients with high metabolic or clearance rates, simply increasing the dose may not achieve effective plasma concentrations.
Here, extending the drug’s half-life through chemical modifications or adjunct therapy can help sustain therapeutic plasma levels.
For example, antibiotics such as penicillin are eliminated rapidly. Probenecid is co-administered to competitively inhibit their elimination, enhancing drug efficacy and duration.
Augmentin, a combination of amoxicillin and clavulanic acid uses a similar strategy. Clavulanic acid, a suicide inhibitor of bacterial ꞵ-lactamase, protects amoxicillin from degradation and expands its spectrum against resistant strains.
繁體中文
